13321_2018_257_MOESM1_ESM.docx Additional file 1. Contains tables showing eM scores (ST1) and measured Tanimoto similarities scores for 22 predicted DrugBank HLA-B*57 01 HLA-B*57 01ounds using interaction fingerprint descriptors (ST2).
This new study attempts to demonstrate the usefulness of a novel molecular docking workflow for identifying HLA-B*57 01 HLA-B*57 01ounds from the wholiablegBank database.
This study by Metushi et al. [34] represents a full in silico to in vitro screening for HLA-B*57 01 HLA-B*57 01ounds from ZINC.
After completing the consensus molecular docking using peptides P1, P2, and P3, the chemical space of predicted DrugBank HLA-B*57 01 HLA-B*57 01ounds was expliable
Due to limited experimental data for model validation, we developed and applied a three-tiered docking protocol to predict potential HLA-B*57 01 HLA-B*57 01ounds from DrugBank.
In our previous study [44], we conducted an in-depth analysis of the capabilities of structure-based molecular docking as a reliable prediction tool for detecting HLA-B*57 01 HLA-B*57 01ounds.
Using these 22 predicted HLA-B*57 01 HLA-B*57 01ounds, we pliable compoundste weth explanmentolists for the development of an efficollaborateccurate screening assay for T-cell activation to confirm our model's predictive capabilities.
Our docking protocol from tier 1 using crystal 3VRI and peptide P1, as shown in Fig. 1, identified 619 HLA-B*57 01 HLA-B*57 01ounds using both SP and XP scoring functions when peptide P1 is the specific co-binding peptide.
After docking based on two scoring functions, three X-ray crystals 3VRI, 3VRJ, and 3UPR with and without their associated co-binding peptides P1, P2, and P3, respectively, we identified 22 potentially HLA-B*57 01 HLA-B*57 01ounds.
Herein, using all these recent insights into modeling drug-HLA interactions, this new study aims at developing and testing an ensemble docking platform [44] to screen the entire DrugBank database for potentially HLA-B*57 01 HLA-B*57 01ounds that are currentliablenown and/or untested.
